在6053名轻度新冠肺炎患者中，2650人报告嗅觉功能障碍，3403人未报告此症状。4227名被原始毒株感染的参与者中有2223人报告嗅觉功能障碍（52.6%[95%可信区间，51.1%-54.1%]）。而Gamma毒株感染患者的嗅觉功能障碍比例降至27.5%（95%可信区间，24.3%）-30.8%），Delta毒株感染患者42.1%（95%可信区间，37.4%-47.0%），Omicron毒株感染者中嗅觉功能障碍的比例只有5.8%（95%可信区间，4.4%-8.5%）。

Of the 6053 participants with mild COVID-19 in the cohort, 2650 reported olfactory dysfunction (Table 1) and 3403 did not report this symptom. Olfactory dysfunction was reported by 2223 of the 4227 participants (52.6% [95% CI, 51.1%-54.1%]) diagnosed during the period of the original lineages (Table 2). The prevalence decreased to 27.5% (95% CI, 24.3%-30.8%) during Gamma, 42.1% (95% CI, 37.4%-47.0%) during Delta, and 5.8% (95% CI, 4.4%-8.5%) during Omicron.

Tags： JAMA—奥密克戎毒性弱爆了：仅5.8%的奥密克戎感染患者出现嗅觉功能减退